Eric Joseph
Stock Analyst at JP Morgan
(1.29)
# 3,378
Out of 4,839 analysts
136
Total ratings
34.88%
Success rate
-12.57%
Average return
Main Sectors:
Stocks Rated by Eric Joseph
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRME Prime Medicine | Downgrades: Neutral | n/a | $1.23 | - | 5 | May 20, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Overweight | $45 → $44 | $6.56 | +570.73% | 3 | May 9, 2025 | |
| NVAX Novavax | Maintains: Underweight | $9 → $7 | $7.29 | -3.98% | 8 | May 9, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $75 → $67 | $45.47 | +47.35% | 10 | May 7, 2025 | |
| OPK OPKO Health | Initiates: Neutral | n/a | $1.27 | - | 4 | Apr 25, 2025 | |
| BLUE bluebird bio | Upgrades: Neutral | n/a | $4.99 | - | 3 | Feb 24, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Neutral | n/a | $1.35 | - | 4 | Feb 10, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $31 → $30 | $10.03 | +199.10% | 7 | Jan 29, 2025 | |
| IGMS IGM Biosciences | Upgrades: Neutral | n/a | $1.21 | - | 8 | Jan 13, 2025 | |
| VIR Vir Biotechnology | Maintains: Neutral | $10 → $14 | $4.61 | +203.69% | 5 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $63 → $71 | $38.85 | +82.75% | 6 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $43 | $34.24 | +25.58% | 4 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $9.47 | +301.27% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $2.06 | +1,016.50% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $6.12 | +177.78% | 2 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $2.84 | +639.44% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $48 | $17.24 | +178.42% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $5.77 | +73.31% | 4 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.86 | - | 4 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $15 | $1.45 | +934.48% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $34 → $47 | $30.17 | +55.78% | 2 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6 | $1.36 | +341.18% | 4 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $11 → $10 | $4.15 | +141.25% | 2 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $11 | $4.07 | +170.27% | 2 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $41 | $48.99 | -16.31% | 2 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $5 | $0.43 | +1,072.61% | 1 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 → $5 | $0.58 | +759.40% | 2 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.86 | - | 6 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $11 | $2.95 | +273.51% | 6 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $7.88 | - | 2 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 | $4.64 | +2,486.21% | 2 | Feb 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $750 → $300 | $5.69 | +5,172.41% | 2 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.22 | - | 2 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $50 | $4.38 | +1,041.55% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $24 → $9 | $1.53 | +490.16% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.83 | - | 4 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $42 | $2.06 | +1,938.83% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 → $13 | $0.61 | +2,016.23% | 2 | Jan 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $11 | $0.49 | +2,124.47% | 3 | Nov 14, 2018 |
Prime Medicine
May 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.23
Upside: -
Rocket Pharmaceuticals
May 9, 2025
Maintains: Overweight
Price Target: $45 → $44
Current: $6.56
Upside: +570.73%
Novavax
May 9, 2025
Maintains: Underweight
Price Target: $9 → $7
Current: $7.29
Upside: -3.98%
PTC Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $75 → $67
Current: $45.47
Upside: +47.35%
OPKO Health
Apr 25, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.27
Upside: -
bluebird bio
Feb 24, 2025
Upgrades: Neutral
Price Target: n/a
Current: $4.99
Upside: -
Pliant Therapeutics
Feb 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.35
Upside: -
Nurix Therapeutics
Jan 29, 2025
Maintains: Overweight
Price Target: $31 → $30
Current: $10.03
Upside: +199.10%
IGM Biosciences
Jan 13, 2025
Upgrades: Neutral
Price Target: n/a
Current: $1.21
Upside: -
Vir Biotechnology
Jan 9, 2025
Maintains: Neutral
Price Target: $10 → $14
Current: $4.61
Upside: +203.69%
Dec 3, 2024
Maintains: Overweight
Price Target: $63 → $71
Current: $38.85
Upside: +82.75%
Nov 25, 2024
Maintains: Overweight
Price Target: $30 → $43
Current: $34.24
Upside: +25.58%
Nov 19, 2024
Initiates: Overweight
Price Target: $38
Current: $9.47
Upside: +301.27%
Nov 5, 2024
Initiates: Overweight
Price Target: $23
Current: $2.06
Upside: +1,016.50%
Oct 17, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $6.12
Upside: +177.78%
Sep 10, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $2.84
Upside: +639.44%
Aug 7, 2024
Maintains: Overweight
Price Target: $45 → $48
Current: $17.24
Upside: +178.42%
Aug 6, 2024
Maintains: Underweight
Price Target: $11 → $10
Current: $5.77
Upside: +73.31%
Jul 8, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.86
Upside: -
May 3, 2024
Maintains: Neutral
Price Target: $14 → $15
Current: $1.45
Upside: +934.48%
Feb 23, 2024
Maintains: Overweight
Price Target: $34 → $47
Current: $30.17
Upside: +55.78%
Jan 29, 2024
Upgrades: Neutral
Price Target: $6
Current: $1.36
Upside: +341.18%
Nov 13, 2023
Maintains: Neutral
Price Target: $11 → $10
Current: $4.15
Upside: +141.25%
Oct 19, 2023
Maintains: Overweight
Price Target: $31 → $11
Current: $4.07
Upside: +170.27%
Oct 11, 2023
Maintains: Overweight
Price Target: $62 → $41
Current: $48.99
Upside: -16.31%
Aug 28, 2023
Downgrades: Neutral
Price Target: $15 → $5
Current: $0.43
Upside: +1,072.61%
Aug 28, 2023
Downgrades: Neutral
Price Target: $28 → $5
Current: $0.58
Upside: +759.40%
Aug 10, 2023
Downgrades: Underweight
Price Target: n/a
Current: $2.86
Upside: -
Aug 9, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $2.95
Upside: +273.51%
Nov 29, 2022
Downgrades: Underweight
Price Target: n/a
Current: $7.88
Upside: -
Feb 9, 2022
Upgrades: Neutral
Price Target: $120
Current: $4.64
Upside: +2,486.21%
Jan 7, 2022
Downgrades: Neutral
Price Target: $750 → $300
Current: $5.69
Upside: +5,172.41%
Oct 8, 2021
Downgrades: Underweight
Price Target: n/a
Current: $3.22
Upside: -
Jul 12, 2021
Initiates: Neutral
Price Target: $50
Current: $4.38
Upside: +1,041.55%
Jan 29, 2021
Downgrades: Neutral
Price Target: $24 → $9
Current: $1.53
Upside: +490.16%
Jan 29, 2021
Downgrades: Underweight
Price Target: n/a
Current: $2.83
Upside: -
Feb 24, 2020
Initiates: Overweight
Price Target: $42
Current: $2.06
Upside: +1,938.83%
Jan 24, 2019
Upgrades: Neutral
Price Target: $11 → $13
Current: $0.61
Upside: +2,016.23%
Nov 14, 2018
Maintains: Neutral
Price Target: $35 → $11
Current: $0.49
Upside: +2,124.47%